1. ARBs
(Angiotensin II Receptor Blockers)
Presented by
Mohammed Moshiur Rahaman
Brand Executive
Brand Management Department
Strategic Brand Management Division
The ACME Laboratories Ltd.

2. Indications
 Main Indication :
For the treatment of hypertension
 Other Indications :
1. Diabetic nephropathy (kidney damage due
to diabetes)
2. Congestive heart failure

3. Available ARBs In World
 Losartan
 Candesartan
 Valsartan
 Irbesartan
 Telmesartan
 Eprosartan
 Olmesartan (FDA 2002)
 Azilsartan (FDA 2011)

4. Available ARBs In Bangladesh (3Q, 2012)
Generic
Introduce
(Year)
Market (Crore)
Growth
Losartan
2001
91.99
33.29
Valsartan
2003
10.16
0.53
Olmesartan
2010
8.45
81.11
Irbesartan
2002
2.96
49.56
Telmesartan
2005
0.77
-24.88
Candesarta
n
2003
0.37
-30.76

5. Azilsartan
Olmesartan
Valsatan
Losartan
Generic
Azilsartan Medoxomil INN
Olmesartan Medoxomil USP
Valsartan INN
Losartan Potassium USP
Therapeutic Class
Antihypertensive (ARBs)
Antihypertensive (ARBs)
Antihypertensive (ARBs)
Antihypertensive (ARBs)
Dosage Form
Tablet
Tablet
Tablet
Tablet
Strength
40 mg & 80 mg
10 mg, 20 mg & 40 mg
40 mg, 80 mg & 160 mg
25 mg, 50 mg & 100 mg
Drug Interactions
No significant drug-drug
interactions
No significant drug-drug
interactions
No significant drug-drug
interactions
No significant drug-drug
interactions
Pregnancy category
D
C
C
C
Use in children
Safety and effectiveness
have not been established
Safety and effectiveness
have been established
Safety and effectiveness
have not been established
Safety and effectiveness
have been established
FDA/BNF approval
FDA approved (2011)
FDA approved (2002)
FDA approved (2001)
FDA approved (1995)
Pharmacokinetic data
Bioavailability: 60%
Half-life: 11 hours
Bioavailability: 29%
Half-life: 13 hours
Bioavailability: 25%
Half-life: 6 hours
Bioavailability: 33%
Half-life: 6-9 hours
AT1 affinity
More than 10000 fold
12500 fold
20000 fold
10000 fold
tmax (h)
1.5-3.0 hrs
1.4-2.8 hrs
2 hrs
3-4 hrs

6. Clinical Trails
Azilsartan at its maximal dose has superior
efficacy to both Olmesartan and Valsartan at
their maximal, approved doses without increasing
adverse events. Azilsartan could provide higher
rates of hypertension controls within the ARB
class.
Ref: Hypertension, 2011 Mar, 57 (3): 413-420. Epub 2011 Jan 31
(Pubmed)

8. Price Comparison
Angiotensin II
Receptor Antagonist
Price/Dose
Price/Month
Annual
Price/Patient
Azilsartan
40 mg tablet
$0.735
$22.05
$264.60
80 mg tablet
$0.735
$22.05
$264.60
25 mg tablet
$0.291
$8.73
$104.76
50 mg tablet
$0.0746
$2.238
$26.86
100 mg tablet
$0.1015
$3.045
$36.54
5 mg tablet
$1.0273
$30.819
$369.83
20 mg tablet
$1.1029
$33.087
$397.04
40 mg tablet
$1.1683
$35.049
$420.59
40 mg tablet
$0.3003
$9.009
$108.11
80 mg tablet
$0.3000
$9.00
$108.00
160 mg tablet
$0.3000
$9.00
$108.00
320 mg tablet
$0.6502
$19.506
$234.07
Losartan
Olmesartan
Valsartan